Breaking News, Collaborations & Alliances

Lilly, ImmunoGen in ADC Pact

TAP technology to combine with Lilly MAbs

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Eli Lilly and Co. and ImmunoGen have entered into an antibody-drug conjugate (ADC) collaboration. Lilly will pay an upfront fee of $20 million for rights to take a limited number of exclusive licenses to use ImmunoGen’s maytansinoid Targeted Antibody Payload (TAP) technology with Lilly monoclonal antibodies to develop novel ADC anticancer therapeutics. Daniel Junius, president and chief executive officer of ImmunoGen, commented, “Lilly is a leader in the development of innovative, a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters